EXAMPLE FOUR
ARTEMIS Review â€” CRITICAL: Drug Interaction Causing Virological Failure
Two problems: carbamazepine toxicity (symptomatic) AND carbamazepine-DTG interaction (silent)
Problem 1: Carbamazepine toxicity
ðŸ’Š Cause: Elevated carbamazepine level (14 mcg/mL, therapeutic range 4â€“12)
The headaches, dizziness, nystagmus, ataxia, and tremor are classic carbamazepine toxicity. Hyponatraemia (128) is from carbamazepine-induced SIADH. The clinician correctly identified this.
Problem 2: Virological failure from drug interaction
âš ï¸ CRITICAL: Carbamazepine reduces DTG blood levels by >50%. This is why the viral load is now detectable.
Carbamazepine is a potent enzyme inducer that dramatically lowers DTG levels. The viral load has risen from <50 to 1,240 copies/mL since carbamazepine was added 2 weeks ago. This is NOT an adherence problem â€” it is a drug interaction causing treatment failure. The Uganda Guidelines list carbamazepine as a contraindication with DTG unless the DTG dose is doubled.

Suggested Management Plan
âœ… AGREE
Clinician's plan: Reduce carbamazepine dose
Supports: Reduce carbamazepine dose and monitor levels â€” symptoms should improve.
ðŸ”„ REVIEW
Clinician's plan: Concerned about detectable viral load but unsure of cause
Consider: The detectable viral load is caused by the carbamazepine-DTG interaction. Two options to discuss with the neurology team:
Option A (preferred): Switch carbamazepine to a non-interacting anticonvulsant â€” sodium valproate (can increase current dose), lamotrigine, or levetiracetam.
Option B: If carbamazepine cannot be stopped, add an extra DTG 50 mg tablet taken 12 hours after the daily TLD dose (making DTG 50 mg twice daily).
Reason: Uganda Guidelines: DTG is contraindicated with carbamazepine/phenytoin/phenobarbital unless DTG dose is increased to 50 mg BD.
âž• ADD
Not in current plan
Consider adding: Correct hyponatraemia (sodium 128). Monitor sodium levels.
Reason: Carbamazepine causes SIADH. May improve with dose reduction but needs monitoring. Fluid restrict if severe.
âž• ADD
Not in current plan
Consider adding: Recheck viral load in 4â€“6 weeks after resolving the interaction.
Reason: Expect VL to re-suppress once DTG levels are adequate. If VL remains detectable despite corrected interaction and good adherence, then consider resistance testing.

Monitoring: Carbamazepine level in 1 week after dose reduction. Sodium level in 3â€“5 days. Viral load in 4â€“6 weeks. LFTs (ALT already mildly elevated at 68).
Counselling: Explain that the epilepsy medication (carbamazepine) was interfering with the HIV medication, making it less effective. This is why the viral load has gone up â€” it is not because of poor adherence. The doctors will either change the epilepsy medication or adjust the HIV medication dose to fix this. It is very important to inform the HIV clinic whenever ANY new medication is started by another clinic or doctor, so interactions can be checked.
ðŸ“– Uganda Consolidated HIV Guidelines 2022, Section 6.11: DTG contraindications include patients on carbamazepine, phenytoin, phenobarbital.